What is Alkermes?
Headquartered in Dublin, Ireland, Alkermes operates at the intersection of neuroscience and patient-centric drug development. The company specializes in the creation and commercialization of innovative medicines designed to address chronic conditions, including schizophrenia, bipolar disorder, and opioid dependence. By integrating deep scientific research with specialized commercial capabilities, Alkermes has established a unique market position that bridges the gap between early-stage investigational candidates and established therapeutic solutions. Its portfolio is characterized by a commitment to addressing significant unmet medical needs within the central nervous system disease landscape, utilizing both proprietary technology and strategic partnerships to drive innovation.
How much funding has Alkermes raised?
Alkermes has raised a total of $251.2M across 2 funding rounds:
Stock Offering
$1.2M
Share Placement
$250M
Stock Issuance/Offering (1991): $1.2M, investors not publicly disclosed
Share Placement (2014): $250M led by Invesco
Key Investors in Alkermes
Invesco
Invesco Ltd. is a global, publicly owned investment manager that provides a comprehensive range of equity, fixed income, and alternative investment strategies to institutional and retail clients worldwide.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Alkermes?
Looking ahead, Alkermes is poised to leverage its recent capital influx to accelerate its clinical trial milestones and enhance its market reach. The company's strategic roadmap emphasizes the optimization of its existing commercial portfolio while simultaneously pushing forward with high-potential investigational candidates. As the biopharmaceutical industry faces increasing pressure to deliver cost-effective and high-impact treatments, Alkermes is likely to prioritize operational efficiency and data-driven R&D. Investors and stakeholders will be closely monitoring the firm's ability to translate its current financial stability into sustained growth, particularly as it navigates the complexities of global regulatory environments and competitive therapeutic markets. The focus remains on scaling its infrastructure to support the long-term delivery of its neurological health solutions.
See full Alkermes company page
